compounded semaglutide fda warning november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Compounded "semaglutide" is not FDA-approved

Make sure you and your provider agree on the format, and understand that injectable formats have stronger clinical evidence than oral compounded versions

Most Empower vials are mixed at 2.5mg/mL or 5mg/mL depending on the vial size ordered

Side effects and tolerability: Nausea, vomiting, or digestive issues sometimes lead patients to stop treatment

You then need to wait at least 30 minutes before eating, drinking, or taking other oral medications

This means the molecule is designed to activate three metabolic hormone systems simultaneously: GLP-1 signaling associated with appetite and glucose response pathways GIP signaling connected to insulin signaling and nutrient metabolism Glucagon signaling linked to energy mobilization and metabolic flexibility By activating these three hormone pathways at the same time, researchers may observe complex metabolic signaling interactions that cannot be produced by single-receptor compounds

Despite the larger numbers, the principle remains the same: start low, go slow, and escalate carefully